Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2024;19(28):2391-2411.
doi: 10.1080/17435889.2024.2403325. Epub 2024 Oct 9.

Enhancing radiotherapy for melanoma: the promise of high-Z metal nanoparticles in radiosensitization

Affiliations
Review

Enhancing radiotherapy for melanoma: the promise of high-Z metal nanoparticles in radiosensitization

Abolfazl Bemidinezhad et al. Nanomedicine (Lond). 2024.

Abstract

Melanoma is a type of skin cancer that can be challenging to treat, especially in advanced stages. Radiotherapy is one of the main treatment modalities for melanoma, but its efficacy can be limited due to the radioresistance of melanoma cells. Recently, there has been growing interest in using high-Z metal nanoparticles (NPs) to enhance the effectiveness of radiotherapy for melanoma. This review provides an overview of the current state of radiotherapy for melanoma and discusses the physical and biological mechanisms of radiosensitization through high-Z metal NPs. Additionally, it summarizes the latest research on using high-Z metal NPs to sensitize melanoma cells to radiation, both in vitro and in vivo. By examining the available evidence, this review aims to shed light on the potential of high-Z metal NPs in improving radiotherapy outcomes for patients with melanoma.

Keywords: gold nanoparticle; high-Z material; melanoma; radiosensitization; radiotherapy.

Plain language summary

[Box: see text].

PubMed Disclaimer

Conflict of interest statement

The authors have no competing interests or relevant affiliations with any organization or entity with the subject matter or materials discussed in the manuscript. This includes employment, consultancies, honoraria, stock ownership or options, expert testimony, grants or patents received or pending, or royalties.

Similar articles

Cited by

References

    1. Liu Y, Sheikh MS. Melanoma: molecular pathogenesis and therapeutic management. Mol Cell Pharmacol. 2014;6(3):228. - PMC - PubMed
    1. Ward WH, Farma JM. Cutaneous melanoma: etiology and therapy [Internet]. 2017. doi:10.15586/codon.cutaneousmelanoma.2017 - DOI - PubMed
    1. Ali Z, Yousaf N, Larkin J. Melanoma epidemiology, biology and prognosis. EJC supplements. 2013;11(2):81. doi:10.1016/j.ejcsup.2013.07.012 - DOI - PMC - PubMed
    1. Tagliaferri L, Lancellotta V, Fionda B, et al. . Immunotherapy and radiotherapy in melanoma: a multidisciplinary comprehensive review. Human Vaccines & Immunotherapeutics. 2022;18(3):1903827. doi:10.1080/21645515.2021.1903827 - DOI - PMC - PubMed
    1. Domingues B, Lopes JM, Soares P, et al. . Melanoma treatment in review. ImmunoTargets and therapy. 2018;7:35–49. doi:10.2147/ITT.S134842 - DOI - PMC - PubMed

MeSH terms

Substances

LinkOut - more resources